Location History:
- Glen Allen, VA (US) (2000 - 2011)
- Richmond, VA (US) (2019 - 2020)
Company Filing History:
4 out of 402 
1 out of 893 
Years Active: 2000-2020
Title: Innovations in Cancer Treatment: The Contributions of Inventor Paul Dent
Introduction
Paul Dent, an accomplished inventor based in Richmond, VA, has made significant strides in the field of cancer research and treatment. With a total of four patents to his name, Dent has developed innovative therapeutic solutions that may enhance the efficacy of existing treatments. His latest contributions particularly focus on tropism modified cancer terminator viruses.
Latest Patents
One of Dent's most notable patents includes the development of a tropism modified cancer terminator virus (Ad.5/3 CTV; Ad.5/3-CTV-M7). This innovative viral therapy has shown to possess infectivity that is independent of the Coxsackie Adenoviral Receptor (CAR). The Ad.5/3-CTV (Ad.5/3-CTV-M7) can be utilized either on its own or in synergy with other therapeutic agents, such as those enhancing reactive oxygen species (ROS) generation, HDAC inhibitors, MCL-1 inhibitors, and Bcl-2 inhibitors. This novel treatment may be effective particularly in combating various cancers, including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
Career Highlights
Throughout his career, Paul Dent has been involved with significant institutions such as Virginia Commonwealth University and The United States of America as represented by the Department of Veterans Affairs. His work in these esteemed organizations underscores his commitment to advancing cancer therapies and research.
Collaborations
In his journey, Dent has collaborated with esteemed professionals, including Steven Grant and Paul B. Fisher. These partnerships have enhanced his research and contributed to the development of groundbreaking solutions in the field of oncology.
Conclusion
In summary, Paul Dent's innovative approach to cancer treatment through his inventions, particularly the tropism modified cancer terminator virus, showcases the potential for new therapeutic strategies in oncology. His continued work at leading research institutions highlights the importance of collaboration and innovation in the quest to improve cancer therapies.